Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interleukin-6 and severe COVID-19: a systematic review and meta-analysis
Helia Mojtabavi, Amene Saghazadeh, Nima Rezaei
European Cytokine Network (2020) Vol. 31, Iss. 2, pp. 44-49
Open Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

Role of Toll‐like receptors in the pathogenesis of COVID‐19
Shaghayegh Khanmohammadi, Nima Rezaei
Journal of Medical Virology (2021) Vol. 93, Iss. 5, pp. 2735-2739
Open Access | Times Cited: 317
Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review
Kawthar Mohamed, Niloufar Yazdanpanah, Amene Saghazadeh, et al.
Bioorganic Chemistry (2020) Vol. 106, pp. 104490-104490
Open Access | Times Cited: 151
On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?
Elnaz Roohi, Nématollah Jaafari, Farshad Hashemian
Journal of Neuroinflammation (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 142
A systematic review of pregnant women with COVID-19 and their neonates
Mona Mirbeyk, Amene Saghazadeh, Nima Rezaei
Archives of Gynecology and Obstetrics (2021)
Open Access | Times Cited: 132
Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review
Arwa A. Al-Qahtani, Fatimah S. Alhamlan, Ahmed A. Al‐Qahtani
Tropical Medicine and Infectious Disease (2024) Vol. 9, Iss. 1, pp. 13-13
Open Access | Times Cited: 94
The role of IL-6 and IL-6 blockade in COVID-19
Nicola Potere, Alberto Batticciotto, Alessandra Vecchié, et al.
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 6, pp. 601-618
Closed Access | Times Cited: 102
Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects
Giuseppe Lisco, Anna De Tullio, Emilio Jirillo, et al.
Journal of Endocrinological Investigation (2021) Vol. 44, Iss. 9, pp. 1801-1814
Open Access | Times Cited: 100
The acid sphingomyelinase/ceramide system in COVID-19
Johannes Kornhuber, Nicolas Hoertel, Erich Gulbins
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 307-314
Open Access | Times Cited: 97
Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID‐19—Mechanisms and Therapeutic Targets
Adriana Fodor, Brînduşa Tiperciuc, Cezar Login, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 87
Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections
Hilal Ahmad Parray, Shivangi Shukla, Reshma Perween, et al.
Applied Microbiology and Biotechnology (2021) Vol. 105, Iss. 16-17, pp. 6315-6332
Open Access | Times Cited: 73
Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos
O E Babalola, Christopher Bode, A.A. Ajayi, et al.
QJM (2021) Vol. 114, Iss. 11, pp. 780-788
Open Access | Times Cited: 70
Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
Aldo Bonaventura, Alessandra Vecchié, Lorenzo Dagna, et al.
Inflammation Research (2022) Vol. 71, Iss. 3, pp. 293-307
Open Access | Times Cited: 43
Respiratory complications of obesity: from early changes to respiratory failure
Neeraj Shah, Georgios Kaltsakas
Breathe (2023) Vol. 19, Iss. 1, pp. 220263-220263
Open Access | Times Cited: 27
Metabolic Syndrome and COVID-19
Hidekatsu Yanai
Cardiology Research (2020) Vol. 11, Iss. 6, pp. 360-365
Open Access | Times Cited: 64
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19
Shikha Patel, Bhagawati Saxena, Priti Mehta
Heliyon (2021) Vol. 7, Iss. 2, pp. e06158-e06158
Open Access | Times Cited: 49
The role of antirheumatics in patients with COVID-19
Christoffer B Nissen, Savino Sciascia, Danieli Andrade, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 6, pp. e447-e459
Open Access | Times Cited: 42
Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes
Cheng‐Han Chen, Sheng-Wen Lin, Ching‐Fen Shen, et al.
Diagnostics (2022) Vol. 12, Iss. 2, pp. 509-509
Open Access | Times Cited: 36
Indeterminate QuantiFERON Gold Plus Results Reveal Deficient Interferon Gamma Responses in Severely Ill COVID-19 Patients
Jeremy D. Ward, Caleb Cornaby, John L. Schmitz
Journal of Clinical Microbiology (2021) Vol. 59, Iss. 10
Open Access | Times Cited: 41
MR‐proADM as marker of endotheliitis predicts COVID‐19 severity
Luis García de Guadiana‐Romualdo, M.D. Calvo Nieves, María Dolores Rodríguez Mulero, et al.
European Journal of Clinical Investigation (2021) Vol. 51, Iss. 5
Open Access | Times Cited: 40
Immune checkpoint inhibition in COVID-19: risks and benefits
Parmida Sadat Pezeshki, Nima Rezaei
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 9, pp. 1173-1179
Open Access | Times Cited: 39
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
Alessia Alunno, Aurélie Najm, Pedro Machado, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 6, pp. 698-706
Open Access | Times Cited: 38
Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies
Kiarash Saleki, Shakila Yaribash, Mohammad Banazadeh, et al.
European Journal of Pharmacology (2021) Vol. 906, pp. 174248-174248
Open Access | Times Cited: 34
Serial measurement of cytokines strongly predict COVID-19 outcome
Hasan Selçuk Özger, Resul Karakuş, Elif Nazli Kuscu, et al.
PLoS ONE (2021) Vol. 16, Iss. 12, pp. e0260623-e0260623
Open Access | Times Cited: 33
mRNA expression of toll-like receptors 3, 7, 8, and 9 in the nasopharyngeal epithelial cells of coronavirus disease 2019 patients
Zahra Bagheri‐Hosseinabadi, Ebrahim Rezazadeh Zarandi, Mohammad Mirabzadeh, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 26
COVID-19 Biomarkers at the Crossroad between Patient Stratification and Targeted Therapy: The Role of Validated and Proposed Parameters
Manuela Rizzi, Davide D’Onghia, Stelvio Tonello, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7099-7099
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top